Oncology Market (By Cancer Diagnostics & Treatment: Cancer Diagnostics and Cancer Treatment; By Indication: Lungs Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncology Market 

5.1. COVID-19 Landscape: Oncology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncology Market, By Indication

8.1. Oncology Market, by Indication Type, 2023-2032

8.1.1. Lungs Cancer

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Colorectal Cancer

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Breast Cancer

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Liver Cancer

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Bladder Cancer

8.1.5.1. Market Revenue and Forecast (2021-2032)

8.1.6. Head & Neck Cancer

8.1.6.1. Market Revenue and Forecast (2021-2032)

8.1.7. Prostate Cancer

8.1.7.1. Market Revenue and Forecast (2021-2032)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Oncology Market, By Cancer Diagnostics & Treatment

9.1. Oncology Market, by Cancer Diagnostics & Treatment, 2023-2032

9.1.1. Cancer Diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor Biomarkers Test, In Situ Hybridization, Liquid Biopsy)

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Cancer Treatment (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others)

9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Oncology Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Indication (2021-2032)

10.1.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.1.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.1.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Indication (2021-2032)

10.2.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.2.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.2.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Indication (2021-2032)

10.2.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Indication (2021-2032)

10.2.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.3.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.3.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Indication (2021-2032)

10.3.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Indication (2021-2032)

10.3.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.4.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.4.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Indication (2021-2032)

10.4.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Indication (2021-2032)

10.4.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Indication (2021-2032)

10.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Indication (2021-2032)

10.5.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Indication (2021-2032)

10.5.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2021-2032)

Chapter 11. Company Profiles

11.1. Aegerion Pharmaceuticals Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Abbvie Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Ability Pharma

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Acadia Pharmaceuticals Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Amgen Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Takeda Oncology

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Aslan Pharmaceuticals Ltd.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Aspen Pharmacare Holdings Limited.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Astrazeneca

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Athenex, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample